Patents by Inventor Mark Eamon Hayes
Mark Eamon Hayes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230108934Abstract: Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.Type: ApplicationFiled: August 31, 2022Publication date: April 6, 2023Applicant: Ipsen Biopharm Ltd.Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark Eamon Hayes, Charles Noble, Kevin Kesper, Antoine M. Awad, Douglas J. Moore, Andrew J. O'Brien
-
Publication number: 20210228567Abstract: Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.Type: ApplicationFiled: September 3, 2020Publication date: July 29, 2021Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark Eamon Hayes, Charles Noble, Kevin Kesper, Antoine M. Awad, Douglas J. Moore, Andrew J. O'Brien
-
Patent number: 10993914Abstract: Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.Type: GrantFiled: September 11, 2019Date of Patent: May 4, 2021Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark Eamon Hayes, Charles Noble, Kevin Kesper, Antoine M. Awad, Douglas J. Moore, Andrew J. O'Brien
-
Publication number: 20200179371Abstract: Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.Type: ApplicationFiled: July 12, 2019Publication date: June 11, 2020Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark Eamon Hayes, Charles Noble, Kevin Kesper, Antoine M. Awad, Douglas J. Moore, Andrew J. O'Brien
-
Publication number: 20200069586Abstract: Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.Type: ApplicationFiled: September 11, 2019Publication date: March 5, 2020Applicant: Ipsen Biopharm Ltd.Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark Eamon Hayes, Charles Noble, Kevin Kesper, Antoine M. Awad, Douglas J. Moore, Andrew J. O'Brien
-
Patent number: 10456360Abstract: Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.Type: GrantFiled: October 15, 2016Date of Patent: October 29, 2019Assignee: Ipsen Biopharm Ltd.Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark Eamon Hayes, Charles Noble, Kevin Kesper, Antoine M. Awad, Douglas J. Moore, Andrew J. O'Brien
-
Publication number: 20190262331Abstract: Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.Type: ApplicationFiled: May 1, 2018Publication date: August 29, 2019Applicant: Ipsen Biopharm Ltd.Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark Eamon Hayes, Charles Noble, Kevin Kesper, Antoine M. Awad, Douglas J. Moore, Andrew J. O'Brien
-
Publication number: 20190105317Abstract: Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.Type: ApplicationFiled: May 1, 2018Publication date: April 11, 2019Applicant: Ipsen Biopharm Ltd.Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark Eamon Hayes, Charles Noble, Kevin Kesper, Antoine M. Awad, Douglas J. Moore, Andrew J. O'Brien
-
Publication number: 20190017073Abstract: Provided are novel compositions useful for delivering nucleic acids to cells. Also provided are methods for making and using such compositions.Type: ApplicationFiled: July 2, 2018Publication date: January 17, 2019Inventors: Mark Eamon Hayes, Dmitri B. Kirpotin
-
Publication number: 20180296484Abstract: Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.Type: ApplicationFiled: October 15, 2016Publication date: October 18, 2018Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark Eamon Hayes, Charles Noble, Kevin Kesper, Antoine M. Awad, Douglas J. Moore, Andrew J. O'Brien
-
Publication number: 20180110771Abstract: Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.Type: ApplicationFiled: July 10, 2017Publication date: April 26, 2018Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark Eamon Hayes, Charles Noble, Kevin Kesper, Antoine M. Awad, Douglas J. Moore, Andrew J. O'Brien
-
Publication number: 20170319573Abstract: Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.Type: ApplicationFiled: July 27, 2017Publication date: November 9, 2017Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark Eamon Hayes, Charles Noble, Kevin Kesper, Antoine M. Awad, Douglas J. Moore, Andrew J. O'Brien
-
Publication number: 20150140069Abstract: Provided herein is a process for preparing a microparticulate complex of a particle-forming component (“PFC”) and a nucleic acid-like component (“NAC”) in a monophasic composition comprising water and a water-miscible organic solvent. Also provided is a microparticulate complex that comprises a particle-forming component complexed to a nucleic acid-like component, and a composition comprising water and the microparticulate complex. Further provided is a method of delivery of a nucleicacid-like component to a cell or to a patient by contacting the cell with or administering to the patient a composition comprising water and the microparticulate complex described herein. Still further, a charge-changing composition represented by the formula A-X—B is provided.Type: ApplicationFiled: September 30, 2014Publication date: May 21, 2015Inventors: Keelung Hong, Wei Wen Zheng, Daryl C. Drummond, Dmitri B. Kirpotin, Mark Eamon Hayes
-
Patent number: 8883200Abstract: Provided herein is a process for preparing a microparticulate complex of a particle-forming component (“PFC”) and a nucleic acid-like component (“NAC”) in a monophasic composition comprising water and a water-miscible organic solvent. Also provided is a microparticulate complex that comprises a particle-forming component complexed to a nucleic acid-like component, and a composition comprising water and the microparticulate complex. Further provided is a method of delivery of a nucleic acid-like component to a cell or to a patient by contacting the cell with or administering to the patient a composition comprising water and the microparticulate complex described herein. Still further, a charge-changing composition represented by the formula A-X—B is provided.Type: GrantFiled: July 11, 2013Date of Patent: November 11, 2014Assignee: Sutter West Bay HospitalsInventors: Keelung Hong, Wei Wen Zheng, Daryl C. Drummond, Dmitri B. Kirpotin, Mark Eamon Hayes
-
Publication number: 20140017300Abstract: Provided herein is a process for preparing a microparticulate complex of a particle-forming component (“PFC”) and a nucleic acid-like component (“NAC”) in a monophasic composition comprising water and a water-miscible organic solvent. Also provided is a microparticulate complex that comprises a particle-forming component complexed to a nucleic acid-like component, and a composition comprising water and the microparticulate complex. Further provided is a method of delivery of a nucleic acid-like component to a cell or to a patient by contacting the cell with or administering to the patient a composition comprising water and the microparticulate complex described herein. Still further, a charge-changing composition represented by the formula A-X—B is provided.Type: ApplicationFiled: July 11, 2013Publication date: January 16, 2014Applicant: Sutter West bay Hospital, DBA California Pacific Medical CenterInventors: Keelung Hong, Wei-Wen Zheng, Daryl C. Drummond, Dmitri B. Kirpotin, Mark Eamon Hayes
-
Patent number: 8496961Abstract: A process for preparing a microparticulate complex is provided. The process comprises (a) combining a particle-forming component (“PFC”) and a nucleic acid-like component (“NAC”) in a monophasic composition comprising water and a water-miscible, organic solvent to form a mixture wherein the PFC and the NAC are independently molecularly or micellarly soluble in the aqueous/organic solvent system, and (b) reducing the amount of the organic solvent in the mixture. This effects formation of the microparticulate complex of the NAC and the PFC. Also provided is a microparticulate complex that comprises a particle-forming component complexed to a nucleic acid-like component forming an approximately spherical particle, wherein the particle-forming component encloses an interior of the particle containing the nucleic acid-like component and the so-enclosed interior volume has less than about 50% (preferably less than 20%) of the volume containing free water.Type: GrantFiled: May 15, 2003Date of Patent: July 30, 2013Assignee: Sutter West Bay HospitalInventors: Keelung Hong, Wei-Wen Zheng, Daryl C. Drummond, Dmitri B. Kirpotin, Mark Eamon Hayes
-
Publication number: 20090171077Abstract: A process for preparing a microparticulate complex is provided. The process comprises (a) combining a particle-forming component (“PFC”) and a nucleic acid-like component (“NAC”) in a monophasic composition comprising water and a water-miscible, organic solvent to form a mixture wherein the PFC and the NAC are independently molecularly or micellarly soluble in the aqueous/organic solvent system, and (b) reducing the amount of the organic solvent in the mixture. This effects formation of the microparticulate complex of the NAC and the PFC. Also provided is a microparticulate complex that comprises a particle-forming component complexed to a nucleic acid-like component forming an approximately spherical particle, wherein the particle-forming component encloses an interior of the particle containing the nucleic acid-like component and the so-enclosed interior volume has less than about 50% (preferably less than 20%) of the volume containing free water.Type: ApplicationFiled: March 10, 2009Publication date: July 2, 2009Inventors: Keelung Hong, Wei-Wen Zheng, Daryl C. Drummond, Dmitri B. Kirpotin, Mark Eamon Hayes
-
Publication number: 20040037874Abstract: A process for preparing a microparticulate complex is provided. The process comprises (a) combining a particle-forming component (“PFC”) and a nucleic acid-like component (“NAC”) in a monophasic composition comprising water and a water-miscible, organic solvent to form a mixture wherein the PFC and the NAC are independently molecularly or micellarly soluble in the aqueous/organic solvent system, and (b) reducing the amount of the organic solvent in the mixture. This effects formation of the microparticulate complex of the NAC and the PFC. Also provided is a microparticulate complex that comprises a particle-forming component complexed to a nucleic acid-like component forming an approximately spherical particle, wherein the particle-forming component encloses an interior of the particle containing the nucleic acid-like component and the so-enclosed interior volume has less than about 50% (preferably less than 20%) of the volume containing free water.Type: ApplicationFiled: May 15, 2003Publication date: February 26, 2004Inventors: Keelung Hong, Wei-Wen Zheng, Daryl C. Drummond, Dmitri B. Kirpotin, Mark Eamon Hayes